by Rod Raynovich | Jan 24, 2011 | BIOgraph
Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December...
by Rod Raynovich | Jan 21, 2011 | BIOgraph, Reading List
Venture Capitalists invested $21.8B in 2010 an increase of 19% over the prior year. Biotechnology was up 3% over the prior year to $3.7B with 460 deals. Software was the leader rising 20% to $4B. Medical Device was flat year over year with $2.3B invested. ANNUAL...
by Rod Raynovich | Jan 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX,...
by Rod Raynovich | Jan 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down...
by Rod Raynovich | Jan 18, 2011 | BIOgraph
J.P.Morgan 29th Annual Healthcare Conference San Francisco, CA January 9-13 2011 Biotechnology: Bright Prospects For 2011 Rod Raynovich The J.P.Morgan Healthcare Conference was a hot ticket in a cold city with over 8500 attendees at the St.Francis Westin Hotel....
by Rod Raynovich | Jan 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the...
by Rod Raynovich | Jan 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Stay the Course for Now We will review our holdngs next week and rebalance if necessary. Overall it has been a good week with biotech indices up about 2%. Late January is always a good time for a correction but for now it is “don’t fight the FED,...
by Rod Raynovich | Jan 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics announced today that it signed a definitive merger agreement with IDEX Corp.(IEX) for $1.35 net cash to the seller subject to adjustment as provided in the merger agreement. The $1.35 price represents about a 58% premium over recent trading and a 69%...
by Rod Raynovich | Jan 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
We will be attending the JPMorgan Healthcare Conference in San Francisco next week looking for new ideas. Healthcare overall has been a laggard (up 1.87% vs 11.47% S&P for one year period) but subsectors such as diagnostics, tools, large cap drugs and selected...
by Rod Raynovich | Jan 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Diagnostics and Tools 2010 Original Price Price % Ret Recomm YrEnd’10 Abaxis ABAX 2/2/09 15 26.85 79 CardioV.Sys. CSII 11/5/10 7.15 11.66 63 Celera CRA 3/28/10 7 6.3 -10 Exact Sci EXAS 12/10/10 5.6 5.98 6.8 GenProbe GPRO 2/2/09 45 58.35 29.7 Illumina ILMN 2/2/09...
